ELOVL2 and prostate carcinoma: Of note, SPOP (18%), FH (9%), ELOVL2 (5%) and ACADL (5%) were significantly altered in PCa cohorts (Supplementary Figure 3A, 333 samples; Primary Prostate Carcinomas; TCGA, Cell 2015) [32].